You are here: Industry Insights > REVLIMID

News List

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss fiercepharma
January 08, 2019
Executives from Bristol-Myers Squibb and Celgene were just a few minutes into a Q&A with investors about their newly announced $74 billion merger when longtime biotech analyst Tim Anderson raised a troubling question.
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss fiercepharma
January 08, 2019
Executives from Bristol-Myers Squibb and Celgene were just a few minutes into a Q&A with investors about their newly announced $74 billion merger when longtime biotech analyst Tim Anderson raised a troubling question.
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma fiercepharma
November 05, 2018
Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win.
Revlimid demonstrates positive phase III results in Indolent NHL GlobalData Healthcare
August 20, 2018
Celgene has announced positive new data for its leading blockbuster drug, Revlimid (lenalidomide), which earned revenues of $8.2bn in 2017.
Global Top 10 Best-selling Drugs W&D
July 05, 2018
This article summarizes and introduces the global top 10 best-selling drugs, to present the readers an impression thereon.
Celgene hikes price of Revlimid to mask poor Q3 results pharmafile
October 30, 2017
Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut its guidance through to 2020.
Revlimid boosts survival in myeloma patients post-transplant pharmatimes
July 31, 2017
a significant overall survival (OS) benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation

Previous page 1 2 Next page